20 results
Thumbnail

D2.432 - Therapeutic Efficacy of Platelet-Rich Plasma in Androgenic Alopecia: A Meta-Analysis of Single Versus Double-Blinded Randomized Controlled Trials

Thumbnail

D2.423 - Changes in the expression of regulatory receptors on CD8+ T cytotoxic lymphocytes as a marker of the risk of developing a post COVID-19 condition in patients after a severe course of COVID-19

Thumbnail

D2.427 - Inhibition of the IL-17 pathway in the treatment of systemic vasculitis: molecular biology and case review

Thumbnail

D2.429 - Virus-Specific Regulatory T-Cell Dysregulation in Post-COVID-19 and EBV-Associated Vasculitis

Thumbnail

D2.430 - Automated 24-Hour Quantification of Scratching Behavior Reveals Distinct Physiological and Allergic Pruritus Signatures in Mice

Thumbnail

D3.308 - Kounis Syndrome: the allergic myocardial infarction

Thumbnail

D3.313 - Recurrent Anaphylaxis with Elevated Baseline Tryptase Revealing Hereditary Alpha-Tryptasemia with Mast Cell Activation

Thumbnail

D3.318 - Evaluation of Clinical Predictors and Serum Tryptase Levels in Systemic Mastocytosis

Thumbnail

D3.319 - Clinical Data of Drug Induced Anaphylaxis according to the standardized European Anaphylaxis Registry (NORA)

Thumbnail

D3.320 - Anaphylaxis by Chlorhexidine: A case series

Thumbnail

D3.321 - Cardiac arrest after Iodixanol: a case of non-IgE mediated mast cell activation

Thumbnail

D3.307 - Chlorhexidine-triggered anaphylaxis in a child with multisystem allergy and sickle cell disease: a diagnostic pitfall

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria

Thumbnail

D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project

Thumbnail

D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child

Thumbnail

D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD

Thumbnail

D3.417 - Dupilumab in pediatric patients with severe atopic dermatitis